Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1292412
PUBLISHER: BCC Research | PRODUCT CODE: 1292412
Oncology Biomarkers: Global Markets
PUBLISHED:
PAGES: 186 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Highlights:
The global oncology biomarkers market reached $15.5 billion in 2022, should reach $17.6 billion by 2023 and $35.2 billion by 2028 with a compound annual growth rate (CAGR) of 14.9% during the forecast period of 2023-2028.
Protein biomarkers segment of the global oncology biomarkers market reached $8.8 billion in 2022, should reach $9.9 billion by 2023 and $18.9 billion by 2028 with a CAGR of 13.7% during the forecast period of 2023-2028.
Genomic biomarkers segment of the global oncology biomarkers market reached $5.7 billion in 2022, should reach $6.5 billion by 2023 and $14.1 billion by 2028 with a CAGR of 16.6% during the forecast period of 2023-2028.
Report Scope:
This study provides a comprehensive analysis of oncology biomarkers on a global basis. It aims to offer a range of information, from detailed market analyses within cancer types to overall industry trends, to quantify and qualify the market for products and services in the oncology biomarkers segment. Current and projected market forecasts during the forecast period (2023 to 2028) are discussed. Figures for 2023 are estimated, except where actual results have been reported.
This report includes forecasts by biomarker type, cancer type, application, and region from 2023 through 2028. The report also includes an analysis of leading and emerging competitors in the current worldwide oncology biomarkers market. The competitive environment is examined with a particular focus on how new products and technologies influence the current standard of care.
Report Includes:
- 21 data tables and 60 additional tables
- An in-depth analysis of the global oncology biomarkers market
- Analyses of global market trends, with data from 2020, 2021, 2022, and projections of compound annual growth rates (CAGRs) through 2028
- Characterization and quantification of biomarkers market by type, profiling technology, application, cancer type, and region
- Discussion on market drivers, challenges and key market strategies and trends
- Information on emerging products and technologies, new analytical platforms, novel immunoassays, and bioinformatics tools and discussion on the use of biomarkers in cancer drug development
- Profiles of the competitive landscape with an overview of competitor growth strategies and opportunities
Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche Ltd., Merck KGaA, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.
Product Code: BIO244A
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Methodology and Information Sources
- Geographic Breakdown
- Analyst's Credentials
- BCC Custom Research
- Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market Outlook
Chapter 4 Market and Technology Background
- Overview of Biomarkers
- Classification of Biomarkers
- Types of Biomarkers
- Biomarker Discovery, Verification and Validation
- Overview of Cancer
- Cancer/Oncology Biomarkers
- Oncology Biomarkers Testing Methods
- Oncology Biomarkers Testing Types
- Biomarker Test Development and Marketing
Chapter 5 Market Dynamics
- Drivers
- Rising Incidence of Cancer
- Increasing Use of Biomarkers in Drug Discovery and Development
- Developments in Analytical Technologies and Assay Methods
- Increased Availability and Ease of Biomarker Testing
- Support from Regulatory Agencies
- Barriers
- Inadequate Patient Access to and Insurance Coverage of Biomarker Testing
- Technical Errors and Delayed Test Results
- Low Provider and Patient Awareness
- Suboptimal Tissue Procurement and Triaging
- Shortages of Laboratories and Personnel
Chapter 6 Market Breakdown by Biomarker Type
- Protein Biomarkers
- Protein Biomarkers Profiling Technologies
- Genomic Biomarker
- Genomic Biomarkers Profiling Technologies
- Other Biomarkers
- Metabolomic Biomarkers
- Cellular Biomarkers
- Global Market for Oncology Biomarkers, by Biomarker Type
- Protein Biomarkers
- Genomic Biomarkers
- Other Biomarkers
Chapter 7 Market Breakdown by Application
- Life Science Research
- Risk Assessment and Screening
- Diagnostics
- Prognostics
- Therapeutic Selection and Clinical Trials
- Monitoring
- Response Monitoring
- Recurrence/Minimal Residual Disease (MRD) Monitoring
- Global Market for Oncology Biomarkers by Application
- Life Science Research
- Risk Assessment and Screening
- Diagnostics
- Prognostics
- Therapeutic Selection and Clinical Trials
- Monitoring
Chapter 8 Market Breakdown by Cancer Type
- Market Overview
- Breast Cancer
- Lung Cancer
- Colorectal Cancer (CRC)
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Leukemia
- Others
- Ovarian Cancer
- Liver Cancer
- Thyroid Cancer
- Cervical Cancer
- Kidney Cancer
- Endometrial Cancer
- Global Market for Oncology Biomarkers by Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Leukemia
- Other Cancers
Chapter 9 Market Breakdown by Region
- Global Market for Oncology Biomarkers by Region
- North America
- Market Revenue by Application
- Market Revenue by Country
- Europe
- Market Revenue by Application
- Market Revenue by Country
- Asia-Pacific
- Market Revenue by Application
- Market Revenue by Country
- Rest of World
- Market Revenue by Application
Chapter 10 Impact of COVID-19
- Overview
- Implications on Cancer Diagnosis
- Implications on Cancer Treatment
- Impact on Oncology Biomarkers Market
Chapter 11 Emerging Trends and Technologies in the Market
- Emerging Technologies and Trends in the Market
- Liquid Biopsy
- Circulating Free Nucleic Acids
- Circulating Cell-Free DNA (CfDNA)
- "Organ Agnostic" Biomarker Testing
- PD-L1
- Homologous Recombination Deficiency (HRD)
- Blood Test for Early-Stage Cancer Detection
Chapter 12 Competitive Landscape
- Overview
- Mergers and Acquisitions
- SWOT Analysis for Global Oncology Biomarker Market
- Porter's Five Forces Analysis of Global Oncology Biomarker Market
Chapter 13 Company Profiles
- AGENDIA INC.
- ABBOTT
- AGILENT TECHNOLOGIES INC.
- BIOCARTIS NV
- BIOMERIEUX S.A.
- BIO-RAD LABORATORIES INC.
- BECTON, DICKINSON & CO.
- EXACT SCIENCES CORP.
- F. HOFFMANN-LA ROCHE AG
- GUARDANT HEALTH INC.
- HOLOGIC INC.
- ILLUMINA INC.
- LEICA BIOSYSTEMS
- MERCK KGAA
- MYRIAD GENETICS INC.
- QIAGEN N.V.
- SIEMENS HEALTHINEERS AG
- THERMO FISHER SCIENTIFIC INC.
- VERACYTE INC.
Chapter 14 Appendix: Acronyms
Product Code: BIO244A
List of Tables
- Summary Table : Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028
- Table 1 : Different Categories of Biomarkers
- Table 2 : Multiple Paths to Market for Biomarker Test
- Table 3 : Biomarkers: Drug Development
- Table 4 : FDA Issued Letters of Support to Cancer Biomarkers
- Table 5 : Three Biggest Barriers to Biomarker Testing
- Table 6 : Selected Protein Biomarkers Used in Oncology
- Table 7 : Examples of Genomic Biomarkers
- Table 8 : NGS Methods Used in Oncology
- Table 9 : PMA Approved NGS Oncology Panel, Somatic or Germline Variant Detection System
- Table 10 : Selected Genomic Biomarkers Used in Oncology
- Table 11 : Potential Applications of CTC-Based Diagnostics
- Table 12 : Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028
- Table 13 : FDA Novel Drug Approvals with Predictive Biomarkers, Jan. 2021-Jan. 2023
- Table 14 : Total Number of Biomarkers Used in FDA Approved Therapeutic Selection Tests or CDx, by Cancer Type, 2022
- Table 15 : Global Market for Oncology Biomarkers, by Application, Through 2028
- Table 16 : NIH Funding for Cancer Research, by Cancer Type, Through 2024
- Table 17 : Total Number of Drugs with Approved CDx, by Cancer Type, 2021
- Table 18 : Estimated Numbers for All Cancers Excl. Non-Melanoma Skin Cancer in 2020
- Table 19 : Selected Key Biomarkers for Breast Cancer
- Table 20 : Biomarkers Used in Breast Cancer Therapy Selection
- Table 21 : Selected Key Biomarkers for Lung Cancer
- Table 22 : Biomarkers Used in Lung Cancer Therapy Selection
- Table 23 : Selected CRC Screening Products/Tests
- Table 24 : Selected Key Biomarkers for CRC
- Table 25 : Biomarkers Used in CRC Therapy Selection
- Table 26 : Selected Prostate Cancer Screening Tests
- Table 27 : Biomarkers Used in Prostrate Cancer Therapy Selection
- Table 28 : Selected Key Biomarkers for Prostate Cancer
- Table 29 : Selected Key Biomarkers for Bladder Cancer
- Table 30 : Biomarkers Used in Bladder Cancer Therapy Selection
- Table 31 : Selected Key Biomarkers for Melanoma
- Table 32 : Biomarkers Used in Melanoma Therapy Selection
- Table 33 : Selected Key Biomarkers for Leukemia
- Table 34 : Biomarkers Used in Leukemia Therapy Selection
- Table 35 : Selected Key Biomarkers for Ovarian Cancer
- Table 36 : Biomarkers Used in Ovarian Cancer Therapy Selection
- Table 37 : Global Market for Oncology Biomarkers, by Cancer Type, Through 2028
- Table 38 : Global Market for Breast Cancer Biomarkers, by Biomarker Type, Through 2028
- Table 39 : Global Market for Lung Biomarkers, by Biomarker Type, Through 2028
- Table 40 : Global Market for Colorectal Cancer Biomarkers, by Biomarker Type, Through 2028
- Table 41 : Global Market for Prostate Cancer Biomarkers, by Biomarker Type, Through 2028
- Table 42 : Global Market for Bladder Cancer Biomarkers, by Biomarker Type, Through 2028
- Table 43 : Global Market for Melanoma Biomarkers, by Biomarker Type, Through 2028
- Table 44 : Global Market for Leukemia Biomarkers, by Biomarker Type, Through 2028
- Table 45 : Global Market for Other Cancers Biomarkers, by Biomarker Type, Through 2028
- Table 46 : Global Market for Oncology Biomarkers, by Region, Through 2028
- Table 47 : Estimated Numbers of New Cases and Deaths for Common Cancer Type in the U.S. in 2023
- Table 48 : North American Market for Oncology Biomarkers, by Application, Through 2028
- Table 49 : North American Market for Oncology Biomarkers, by Country, Through 2028
- Table 50 : Challenges to Biomarker Testing in Europe
- Table 51 : Demographic, Cancer and Healthcare Statistics for Selected European Countries
- Table 52 : Estimated Cancer Incidence and Mortality, Age Standardized Rate in the EU Countries, by Cancer Type, 2020
- Table 53 : European Market for Oncology Biomarkers, by Application, Through 2028
- Table 54 : European Market for Oncology Biomarkers, by Country, Through 2028
- Table 55 : Oncology Statistics in Select Asia-Pacific Countries, 2020
- Table 56 : Estimated Cancer Cases in Asia-Pacific Countries, by Notable Cancer Types, 2020
- Table 57 : Asia-Pacific Market for Oncology Biomarkers, by Application, Through 2028
- Table 58 : Asia-Pacific Market for Oncology Biomarkers, by Country, Through 2028
- Table 59 : Cancer Statistics, South America and Africa, 2020
- Table 60 : RoW Market for Oncology Biomarkers, by Application, Through 2028
- Table 61 : Selected CfDNA-Based Cancer Tests
- Table 62 : Leading Market Players in Oncology Biomarkers Market, 2022
- Table 63 : Recent Mergers and Acquisitions in Oncology Biomarkers Market, 2020-2022
- Table 64 : Porter's Five Forces Analysis: Global Oncology Biomarkers Market
- Table 65 : Agilent Technologies Inc.: Selected Key Developments, January 2021-March 2023
- Table 66 : Biocartis: Selected Key Developments, January 2020-March 2023
- Table 67 : Bio-Rad Laboratories: Selected Key Developments, January 2020-March 2023
- Table 68 : BD: Business Segments
- Table 69 : BD: Selected Key Developments, January 2020-March 2023
- Table 70 : Exact Sciences Corp.: Key Developments, January 2021 to December 2022
- Table 71 : Roche: Selected Recent Developments, January 2021 to March 2023
- Table 72 : Guardant Health: Key Developments, 2021-2022
- Table 73 : Hologic Inc.: Key Developments, January 2021 to December 2022
- Table 74 : Illumina Inc: Key Developments, 2021 and 2022
- Table 75 : Leica Biosystems: Key Developments, January 2021 to December 2022
- Table 76 : Myriad Genetics: Key Developments, January 2021 to December 2022
- Table 77 : Qiagen: Key Recent Developments, 2021-April 2023
- Table 78 : Thermo Fisher Scientific Inc.: Key Developments, January 2021 to January 2023
- Table 79 : Veracyte: Key Recent Developments, Jan 2021-Jan 2023
- Table 80 : Abbreviations Used in This Report
List of Figures
- Summary Figure : Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028
- Figure 1 : Biomarker Types Categorized by Application and Use in Drug Development and Disease Management
- Figure 2 : Molecular and Imaging Biomarkers
- Figure 3 : Biomarker Discovery, Verification and Validation
- Figure 4 : Cancer Care Spectrum
- Figure 5 : Types of Biomarker Testing and Their Definitions
- Figure 6 : Biomarkers in Personalized Treatment
- Figure 7 : Global Cancer Incidence, by Region, 2020
- Figure 8 : Global Cancer Incidence, by Region, 2020 vs. 2040
- Figure 9 : Distribution Shares of R&D Investment in Drug Development, by Function, 2020
- Figure 10 : Overview of Biomarker Test Benefits for Each Stakeholder
- Figure 11 : Barriers to the Use of Biomarker Tests Throughout the Patient Journey
- Figure 12 : Top Barriers to Biomarker Testing in the U.S., 2021
- Figure 13 : Common Biomarker Testing Methodologies
- Figure 14 : Four Main Classes of Genomic Alterations
- Figure 15 : Types of Genomic Biomarkers
- Figure 16 : Genomic Biomarker Testing Methods
- Figure 17 : Key Advantages of NGS for Precision Oncology Applications
- Figure 18 : Evolution of Biomarkers in Clinical Practice
- Figure 19 : Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028
- Figure 20 : Global Market Shares of Oncology Biomarkers, by Biomarker Type, 2022
- Figure 21 : Hallmark of Cancer
- Figure 22 : Stages of Cancer
- Figure 23 : Companion Diagnostics Co-Development Process from Biomarker Discovery to Regulatory Approval
- Figure 24 : Clinical Applications of Biomarkers in Oncology
- Figure 25 : Global Market for Oncology Biomarkers, by Application, 2020-2028
- Figure 26 : Global Market Shares of Oncology Biomarkers, by Application, 2022
- Figure 27 : Five-Year Overall Survival Rates in the U.S., by Cancer Type
- Figure 28 : Global Market for Oncology Biomarkers, by Cancer Type, 2020-2028
- Figure 29 : Global Market Shares of Oncology Biomarkers, by Cancer Type, 2022
- Figure 30 : Global Market Shares of Breast Cancer Biomarkers, by Biomarker Type, 2022
- Figure 31 : Global Market Shares of Lung Biomarkers, by Biomarker Type, 2022
- Figure 32 : Global Market Shares of Colorectal Cancer Biomarkers, by Biomarker Type, 2022
- Figure 33 : Global Market Shares of Prostate Cancer Biomarkers, by Biomarker Type, 2022
- Figure 34 : Global Market Shares of Bladder Cancer Biomarkers, by Biomarker Type, 2022
- Figure 35 : Global Market Shares of Melanoma Biomarkers, by Biomarker Type, 2022
- Figure 36 : Global Market Shares of Leukemia Biomarkers, by Biomarker Type, 2022
- Figure 37 : Global Market Shares of Other Cancers Biomarkers, by Biomarker Type, 2022
- Figure 38 : Global Market for Oncology Biomarkers, by Region, 2020-2028
- Figure 39 : Global Market Shares of Oncology Biomarkers, by Region, 2022
- Figure 40 : NIH's Cancer and Cancer Genomics Research Funding, by Year, 2018-2024
- Figure 41 : North American Market Shares of Oncology Biomarkers, by Application, 2022
- Figure 42 : European Market Shares of Oncology Biomarkers, by Application, 2022
- Figure 43 : Asia-Pacific Market Shares of Oncology Biomarkers, by Application, 2022
- Figure 44 : RoW Market Shares of Oncology Biomarkers, by Application, 2022
- Figure 45 : Emerging Trends/Technologies in the Oncology Biomarkers Market
- Figure 46 : Advantages of Liquid Biopsy
- Figure 47 : PubMed Article Count: "Liquid Biopsy", 2014-2022
- Figure 48 : Pan-Cancer Genomic Biomarkers
- Figure 49 : SWOT Analysis of the Global Oncology Biomarkers Market
- Figure 50 : Abbott: Diagnostics Revenue, 2020-2022
- Figure 51 : Abbott: Diagnostics Market Share, by Business Segment, 2022
- Figure 52 : Agilent Technologies Inc.: Diagnostics and Genomics Revenue, 2020-2022
- Figure 53 : Biocartis: Annual Net Revenue, 2020-2022
- Figure 54 : Biocartis: Market Share, by Business Segment, 2022
- Figure 55 : BioMerieux SA: Annual Net Revenue, 2020-2022
- Figure 56 : BioMerieux SA: Market Share, by Application, 2022
- Figure 57 : Bio-Rad Laboratories: Annual Net Revenue, 2020-2022
- Figure 58 : Bio-Rad Laboratories: Market Share, by Business Segment, 2022
- Figure 59 : BD's Biosciences Segment: Annual Revenue, 2020-2022
- Figure 60 : Exact Sciences Corp.: Annual Net Revenue, 2020-2022
- Figure 61 : Exact Sciences Corp.: Market Share, by Business Segment, 2022
- Figure 62 : F. Hoffmann-La Roche Ltd.'s Diagnostics Division: Annual Revenue, 2020-2022
- Figure 63 : F. Hoffmann-La Roche Ltd.'s Diagnostics Division: Market Share, by Customer Area, 2022
- Figure 64 : Guardant Health: Annual Net Revenue, 2020-2022
- Figure 65 : Guardant Health: Market Share, by Segment, 2022
- Figure 66 : Hologic Inc.: Annual Net Revenue, 2020-2022
- Figure 67 : Hologic Inc.: Market Share, by Business Segment, 2022
- Figure 68 : Illumina Inc.: Annual Net Revenue, 2020-2022
- Figure 69 : Illumina Inc.: Market Share, by Business Segment, 2022
- Figure 70 : Merck KGaA: Annual Revenue, 2020-2022
- Figure 71 : Merck KGaA: Market Share, by Business Segment, 2022
- Figure 72 : Myriad Genetics: Annual Net Revenue, 2021 and 2022
- Figure 73 : Myriad Genetics: Market Share, by Business Segment, 2022
- Figure 74 : Qiagen: Annual Net Revenue, 2020-2022
- Figure 75 : Qiagen: Market Share, by Product Type, 2022
- Figure 76 : Siemens Healthineers AG: Annual Net Revenue, 2020-2022
- Figure 77 : Siemens Healthineers AG: Market Share, by Business Segment, 2022
- Figure 78 : Thermo Fisher Scientific Inc.: Annual Revenue, 2020-2022
- Figure 79 : Thermo Fisher Scientific Inc.: Market Share, by Business Segment, 2022
- Figure 80 : Veracyte: Annual Revenue, 2020-2022
- Figure 81 : Veracyte: Market Share, by Business Segment, 2022
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.